Protagonist Therapeutics (PTGX) Stock Forecast & Price Target

Compare

727 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

PTGX Analyst Ratings

Strong Buy

12 Buy

1 Hold

0 Sell

Based on 13 analysts giving stock ratings to

Protagonist

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

PTGX Stock 12 Month Forecast

Average Price Target

$94.54

▲(17.88% Upside)

Based on 13 Wall Street analysts offering 12 month price targets for Protagonist Therapeutics in the last 3 months. The average price target is $94.54 with a high forecast of $115.00 and a low forecast of $65.00. The average price target represents a 17.88% change from the last price of $80.20.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"36":"$36","56":"$56","76":"$76","96":"$96","116":"$116"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":115,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$115.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":94.54,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$94.54</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":65,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$65.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[36,56,76,96,116],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,87.34,89.46769230769232,91.59538461538462,93.72307692307693,95.85076923076923,97.97846153846154,100.10615384615384,102.23384615384616,104.36153846153846,106.48923076923077,108.61692307692307,110.74461538461539,112.87230769230769,{"y":115,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,87.34,87.89384615384616,88.44769230769231,89.00153846153846,89.55538461538463,90.10923076923078,90.66307692307693,91.21692307692308,91.77076923076923,92.32461538461538,92.87846153846155,93.4323076923077,93.98615384615385,{"y":94.54,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,87.34,85.62153846153846,83.90307692307692,82.18461538461538,80.46615384615384,78.7476923076923,77.02923076923076,75.31076923076924,73.5923076923077,71.87384615384616,70.15538461538462,68.43692307692308,66.71846153846154,{"y":65,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":38.6,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.8,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.59,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.88,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.99,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.15,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.21,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.83,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.85,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":64,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":78.62,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85.64,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":87.34,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$115.00

Average Price Target$94.54

Lowest Price Target$65.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Yun Zhong

Wedbush

$86

Buy

7.23%

Upside

Reiterated

01/06/26

Advancing, De-Risked Pipeline and Near-Term Regulatory Catalysts Underpin Protagonist Therapeutics Buy Rating

Srikripa Devarakonda

Truist Financial

$88→$110

Buy

37.16%

Upside

Reiterated

01/05/26

Analysts Offer Insights on Healthcare Companies: McKesson (NYSE: MCK) and Protagonist Therapeutics (NASDAQ: PTGX)

Joanne Wuensch

Citi

$115

Buy

43.39%

Upside

Reiterated

01/05/26

Analysts Are Bullish on Top Healthcare Stocks: Amylyx Pharmaceuticals Inc (AMLX), Agilent (A)

Unknown Analyst

Jefferies

Not Ranked

Jefferies

$95

Buy

18.45%

Upside

Reiterated

12/19/25

Jefferies Sticks to Their Buy Rating for Protagonist Therapeutics (PTGX)

Etzer Darout

Barclays

$88→$108

Buy

34.66%

Upside

Reiterated

12/17/25

Barclays Sticks to Their Buy Rating for Protagonist Therapeutics (PTGX)

Brian Cheng

J.P. Morgan

$81→$93

Buy

15.96%

Upside

Reiterated

11/19/25

J.P. Morgan Keeps Their Buy Rating on Protagonist Therapeutics (PTGX)

Douglas Tsao

H.C. Wainwright

$83.24→$80

Buy

-0.25%

Downside

Reiterated

11/14/25

H.C. Wainwright Reaffirms Their Buy Rating on Protagonist Therapeutics (PTGX)

Richard Law CFA

Goldman Sachs

$47→$65

Hold

-18.95%

Downside

Reiterated

11/10/25

Protagonist Therapeutics price target raised to $65 from $47 at Goldman SachsProtagonist Therapeutics price target raised to $65 from $47 at Goldman Sachs

Jonathan Wolleben

Citizens JMP

$69→$102

Buy

27.18%

Upside

Reiterated

11/07/25

Protagonist Therapeutics price target raised to $102 from $69 at Citizens JMPProtagonist Therapeutics price target raised to $102 from $69 at Citizens JMP

Tara Bancroft

TD Cowen

$65→$90

Buy

12.22%

Upside

Reiterated

11/07/25

Promising Developments and Strategic Progress at Protagonist Therapeutics Drive Buy Rating

Kaveri Pohlman

Clear Street

$74→$91

Buy

13.47%

Upside

Reiterated

11/07/25

Protagonist Therapeutics price target raised to $91 from $74 at Clear StreetProtagonist Therapeutics price target raised to $91 from $74 at Clear Street

Julian Harrison

BTIG

$82

Buy

2.24%

Upside

Reiterated

11/03/25

Analysts Offer Insights on Healthcare Companies: Protagonist Therapeutics (NASDAQ: PTGX) and Perspective Therapeutics (NYSE MKT: CATX)

Evan Seigerman

BMO Capital

$72→$112

Buy

39.65%

Upside

Reiterated

10/13/25

Protagonist Therapeutics (PTGX) Gets a Buy from BMO Capital

Faisal Khurshid

Leerink Partners

Buy

―

Reiterated

09/18/25

Unknown Analyst

Roth MKM

Not Ranked

Roth MKM

$72

Buy

-10.22%

Downside

Initiated

09/17/25

Protagonist Therapeutics (PTGX) Initiated with a Buy at Roth MKM

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Yun Zhong

Wedbush

$86

Buy

7.23%

Upside

Reiterated

01/06/26

Advancing, De-Risked Pipeline and Near-Term Regulatory Catalysts Underpin Protagonist Therapeutics Buy Rating

Srikripa Devarakonda

Truist Financial

$88→$110

Buy

37.16%

Upside

Reiterated

01/05/26

Analysts Offer Insights on Healthcare Companies: McKesson (NYSE: MCK) and Protagonist Therapeutics (NASDAQ: PTGX)

Joanne Wuensch

Citi

$115

Buy

43.39%

Upside

Reiterated

01/05/26

Analysts Are Bullish on Top Healthcare Stocks: Amylyx Pharmaceuticals Inc (AMLX), Agilent (A)

Unknown Analyst

Jefferies

Not Ranked

Jefferies

$95

Buy

18.45%

Upside

Reiterated

12/19/25

Jefferies Sticks to Their Buy Rating for Protagonist Therapeutics (PTGX)

Etzer Darout

Barclays

$88→$108

Buy

34.66%

Upside

Reiterated

12/17/25

Barclays Sticks to Their Buy Rating for Protagonist Therapeutics (PTGX)

Brian Cheng

J.P. Morgan

$81→$93

Buy

15.96%

Upside

Reiterated

11/19/25

J.P. Morgan Keeps Their Buy Rating on Protagonist Therapeutics (PTGX)

Douglas Tsao

H.C. Wainwright

$83.24→$80

Buy

-0.25%

Downside

Reiterated

11/14/25

H.C. Wainwright Reaffirms Their Buy Rating on Protagonist Therapeutics (PTGX)

Richard Law CFA

Goldman Sachs

$47→$65

Hold

-18.95%

Downside

Reiterated

11/10/25

Protagonist Therapeutics price target raised to $65 from $47 at Goldman SachsProtagonist Therapeutics price target raised to $65 from $47 at Goldman Sachs

Jonathan Wolleben

Citizens JMP

$69→$102

Buy

27.18%

Upside

Reiterated

11/07/25

Protagonist Therapeutics price target raised to $102 from $69 at Citizens JMPProtagonist Therapeutics price target raised to $102 from $69 at Citizens JMP

Tara Bancroft

TD Cowen

$65→$90

Buy

12.22%

Upside

Reiterated

11/07/25

Promising Developments and Strategic Progress at Protagonist Therapeutics Drive Buy Rating

Kaveri Pohlman

Clear Street

$74→$91

Buy

13.47%

Upside

Reiterated

11/07/25

Protagonist Therapeutics price target raised to $91 from $74 at Clear StreetProtagonist Therapeutics price target raised to $91 from $74 at Clear Street

Julian Harrison

BTIG

$82

Buy

2.24%

Upside

Reiterated

11/03/25

Analysts Offer Insights on Healthcare Companies: Protagonist Therapeutics (NASDAQ: PTGX) and Perspective Therapeutics (NYSE MKT: CATX)

Evan Seigerman

BMO Capital

$72→$112

Buy

39.65%

Upside

Reiterated

10/13/25

Protagonist Therapeutics (PTGX) Gets a Buy from BMO Capital

Faisal Khurshid

Leerink Partners

Buy

―

Reiterated

09/18/25

Unknown Analyst

Roth MKM

Not Ranked

Roth MKM

$72

Buy

-10.22%

Downside

Initiated

09/17/25

Protagonist Therapeutics (PTGX) Initiated with a Buy at Roth MKM

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Protagonist Therapeutics

1 Month

xxx

Success Rate

16/23 ratings generated profit

Average Return

+11.04%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 69.57% of your transactions generating a profit, with an average return of +11.04% per trade.

3 Months

xxx

Success Rate

11/13 ratings generated profit

Average Return

+17.61%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 84.62% of your transactions generating a profit, with an average return of +17.61% per trade.

1 Year

Jonathan WollebenCitizens JMP

Success Rate

23/23 ratings generated profit

Average Return

+84.19%

reiterated a buy rating 2 months ago

Copying Jonathan Wolleben's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +84.19% per trade.

2 Years

xxx

Success Rate

23/23 ratings generated profit

Average Return

+198.01%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +198.01% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

PTGX Analyst Recommendation Trends

Rating

Sep 25

Oct 25

Nov 25

Dec 25

Jan 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, PTGX has received 19 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. PTGX average Analyst price target in the past 3 months is 94.54.

Each month's total comprises the sum of three months' worth of ratings.

PTGX Financial Forecast

PTGX Earnings Forecast

Next quarter’s earnings estimate for PTGX is -$0.34 with a range of -$0.78 to $2.19. The previous quarter’s EPS was -$0.62. PTGX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year PTGX has Performed in-line its overall industry.

PTGX Sales Forecast

Next quarter’s sales forecast for PTGX is $26.81M with a range of $0.00 to $225.00M. The previous quarter’s sales results were $4.71M. PTGX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year PTGX has Performed in-line its overall industry.

PTGX Stock Forecast FAQ

What is PTGX’s average 12-month price target, according to analysts?

Based on analyst ratings, Protagonist Therapeutics’s 12-month average price target is 94.54.

What is PTGX’s upside potential, based on the analysts’ average price target?

Protagonist Therapeutics has 17.88% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is PTGX a Buy, Sell or Hold?

Protagonist Therapeutics has a consensus rating of Strong Buy which is based on 12 buy ratings, 1 hold ratings and 0 sell ratings.

What is Protagonist Therapeutics’s price target?

The average price target for Protagonist Therapeutics is 94.54. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $115.00 ,the lowest forecast is $65.00. The average price target represents 17.88% Increase from the current price of $80.2.

What do analysts say about Protagonist Therapeutics?

Protagonist Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 13 Wall Streets Analysts.

How can I buy shares of PTGX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Protagonist Therapeutics (PTGX) Stock Forecast & Price Target

PTGX Analyst Ratings

PTGX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Protagonist Therapeutics

PTGX Analyst Recommendation Trends

PTGX Financial Forecast

PTGX Earnings Forecast

PTGX Sales Forecast

PTGX Stock Forecast FAQ

Detailed List of Analyst Forecasts